Evidence map›Paper›PMID 38885370›Full record

Observational studyRheumatology (Oxford, England)2025

Assessment of damage in Takayasu's arteritis.

Tanaz A Kermani, Antoine G Sreih, David Cuthbertson, Nader A Khalidi, Curry L Koening, Carol A Langford, Carol A McAlear, Paul A Monach, Larry Moreland, Christian Pagnoux and 4 more

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Management of Takayasu Arteritis - A 2026 Update.Current rheumatology reports · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Tanaz A KermaniDivision of Rheumatology, University of California, Los Angeles, CA, USA.ORCID 0000-0002-7335-7321
Antoine G SreihDivision of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA.
David CuthbertsonDepartment of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, USA.
Nader A KhalidiDivision of Rheumatology, St Joseph's Healthcare, McMaster University, Hamilton, ON, Canada.
Curry L KoeningDivision of Rheumatology, University of Texas Dell Medical School, TX, USA.
Carol A LangfordDivision of Rheumatology, Cleveland Clinic, Cleveland, OH, USA.
Carol A McAlearDivision of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA.
Paul A MonachSection of Rheumatology, VA Boston Healthcare System, Boston, MA, USA.
Larry MorelandDivision of Rheumatology, University of Colorado, CO, USA.
Christian PagnouxDivision of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada.
Rennie L RheeDivision of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-4907-0304
Philip SeoDivision of Rheumatology, Johns Hopkins University, Baltimore, MD, USA.
Kenneth J WarringtonDivision of Rheumatology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-7708-2487
Peter A MerkelDivision of Rheumatology and Division of Epidemiology, University of Pennsylvania, Philadelphia, PA, USA.

Funding

VCRC-VF FellowshipU54AR057319 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI MERKEL, PETER A · 2009 to 2020
$12.5M
VASCULITIS CLINICAL RESEARCH NETWORK (VCRN): RARE DISEASEU54RR019497 · NCRR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MERKEL, PETER A · 2003 to 2008
$6.1M
NCRR NIH HHS U54 RR019497NIAMS NIH HHS U54 AR057319Rare Diseases Clinical Research Network
6 · The paper itself

Abstract

objectivesTo evaluate damage and clinical characteristics associated with damage in Takayasu's arteritis (TAK).

methodsPatients with TAK enrolled in a multicentre, prospective, observational study underwent standardized damage assessment every 6 months using the Vasculitis Damage Index (VDI) and the Large-Vessel Vasculitis Index of Damage (LVVID).

resultsThe study included 236 patients with TAK: 92% female, 81% Caucasian; median (25th, 75th percentile) disease duration = 2.6 (0.12, 6.9) years. Eighty-four percent had follow-up: median (25th, 75th) duration 4.1 (1.9, 7.5) years. Items of damage were present in 89% on VDI, 87% on LVVID, in the peripheral vascular (76% VDI, 74% LVVID) and cardiac (40% VDI, 45% LVVID) systems. During follow-up, 42% patients had new damage, including major vessel stenosis/arterial occlusion (8%), limb claudication (6%), hypertension (7%), aortic aneurysm (4%) and bypass surgery (4%). Disease-specific damage accounted for >90% of new items. Older age, relapse and longer duration of follow-up were associated with new damage items; a higher proportion of patients without new damage were on MTX (P <0.05). Among 48 patients diagnosed with TAK within 180 days of enrolment, new damage occurred in 31% on VDI and 52% on LVVID. History of relapse was associated with new damage in the entire cohort while in patients with a recent diagnosis, older age at diagnosis was associated with new damage.

conclusionDamage is present in >80% of patients with TAK even with recent diagnosis and >40% of patients accrue new, mainly disease-specific damage. Therapies for TAK that better control disease activity and prevent damage should be prioritized.

Indexed as

Takayasu ArteritisAdultFemaleHumansMaleMiddle AgedProspective StudiesSeverity of Illness IndexYoung AdultdamageLarge-Vessel Vasculitis Index of DamageTakayasu’s arteritisvasculitis damage index

Identifiers

PMID38885370
PMCPMC12090991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.